<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of uncomplicated falciparum malaria in nonpregnant adults and children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of uncomplicated falciparum malaria in nonpregnant adults and children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of uncomplicated falciparum malaria in nonpregnant adults and children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uncomplicated falciparum malaria consists of symptomatic <em>Plasmodium falciparum</em> infection with a positive parasitologic test and parasitemia &lt;4 percent, in the absence of symptoms consistent with severe malaria  (<a class="graphic graphic_table graphicRef107439" href="/d/graphic/107439.html" rel="external">table 1</a>).</p><p>Issues related to treatment of uncomplicated falciparum malaria in nonpregnant adults and children will be reviewed here. Issues related to treatment of severe malaria, treatment of malaria in pregnant women, and treatment of non-falciparum malaria are discussed separately. (See  <a class="medical medical_review" href="/d/html/5667.html" rel="external">"Treatment of severe malaria"</a> and  <a class="medical medical_review" href="/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment"</a> and  <a class="medical medical_review" href="/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"</a> and  <a class="medical medical_review" href="/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi"</a>.)</p><p>Investigational antimalarial drugs are discussed separately. (See  <a class="medical medical_review" href="/d/html/468.html" rel="external">"Antimalarial drugs: An overview"</a>.)</p><p class="headingAnchor" id="H345141709"><span class="h1">INDICATIONS FOR HOSPITALIZATION</span><span class="headingEndMark"> — </span>Hospitalization permits clinical observation for tolerance of antimalarial therapy, monitoring for reduction in parasitemia (reflecting efficacy of therapy), and advanced management in the case of progression to severe disease. Hospitalization is appropriate for patients in the following categories, who may deteriorate rapidly [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Young children</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised patients</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with no acquired immunity (ie, individuals from nonendemic areas)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hyperparasitemia (4 to 10 percent) but no signs of severe infection; such patients are at increased risk for progression to severe malaria and/or treatment failure</p><p></p><p class="headingAnchor" id="H2597737481"><span class="h1">ANTIMALARIAL SELECTION</span></p><p class="headingAnchor" id="H2238888048"><span class="h2">Within endemic areas</span></p><p class="headingAnchor" id="H1086809905"><span class="h3">General approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment considerations</strong> – The approach to first-line therapy should take into consideration local guidelines, drug sensitivity patterns, and drug availability. <em>P. falciparum</em> may or may not be sensitive to <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a>, as determined by local antimalarial drug resistance data. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management approach</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of combination therapy</strong> – In general, treatment of uncomplicated malaria consists of oral therapy with a combination of two drugs (in the case of <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> resistance) or chloroquine monotherapy (in the case of chloroquine sensitivity) if artemisinin combination therapy (ACT) is not available. The goal of this strategy is to forestall development of further resistance and conserve the agents that are presently effective.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selection of first-line agent</strong> – We are in agreement with the World Health Organization (WHO) which recommends use of ACT for treatment of uncomplicated <em>P. falciparum</em> malaria (irrespective of <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> sensitivity) [<a href="#rid3">3</a>]. However, in the case of chloroquine-sensitive <em>P. falciparum</em> where ACT is not readily available, we favor treatment with chloroquine or <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, in alignment with the recommendations of the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malaria infection in spite of prophylaxis</strong> – Patients can develop malaria despite using chemoprophylaxis; such patients should receive a different antimalarial regimen for treatment. In 2018, 43 United States residents who reported taking and fully adhering to a CDC-recommended prophylaxis regimen developed malaria [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H1706830252"><span class="h4">Selecting an ACT</span><span class="headingEndMark"> — </span>There are numerous artemisinin-based combination therapies (ACTs) available for treatment of uncomplicated <em>P. falciparum</em> malaria (or species not identified) in endemic areas with <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> resistance. We are in agreement with the WHO, which favors first-line therapy with one of the following ACTs  (<a class="graphic graphic_table graphicRef107438" href="/d/graphic/107438.html" rel="external">table 2</a>) [<a href="#rid2">2,3,5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">Artemether-lumefantrine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Artesunate-amodiaquine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Artesunate-mefloquine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Artesunate-pyronaridine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Artesunate-sulfadoxine-pyrimethamine (SP), in areas with known SP sensitivity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dihydroartemisinin-piperaquine (DP), in areas with known piperaquine sensitivity; DP should not be used for treatment of malaria acquired in the greater Mekong subregion (including southwestern Vietnam, western Cambodia, and northeastern Thailand), unless combined with <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a>.</p><p></p><p>ACTs have a low side effect profile, are potent against all blood stages (asexual forms) of malaria, and have the most rapid clearance time relative to other antimalarial drugs  (<a class="graphic graphic_figure graphicRef79113" href="/d/graphic/79113.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. Artemisinins should be administered with a second agent that has a longer half-life than the artemisinin drug to forestall development of artemisinin resistance and to provide an extended duration of drug level to clear parasitemia [<a href="#rid8">8,9</a>]. Administration of artemisinins alone would result in recrudescence (treatment failure) [<a href="#rid10">10</a>]. Dosing of ACTs is summarized in the table  (<a class="graphic graphic_table graphicRef107438" href="/d/graphic/107438.html" rel="external">table 2</a>) [<a href="#rid2">2,5</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> may be diminished as body weight increases; therefore, for patients &gt;65 kg, close follow-up after artemether-lumefantrine treatment (or use of an alternative treatment such as <a class="drug drug_general" data-topicid="8704" href="/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>) warrants consideration. This was illustrated in one study including more than 390 episodes of falciparum malaria, lower efficacy of artemether-lumefantrine was observed among patients &gt;65 kg than patients ≤65 kg (90 percent [95% CI 79-96 percent] versus 100 percent [95% CI 66-100 percent]) [<a href="#rid11">11</a>]. Similarly, in another study including 165 patients, 28-day parasitologic cure rates were lower among patients &gt;65 kg (93.4 percent [95% CI 85.3-97.8 percent] versus 100 percent [95% CI 92.5-100.0 percent]) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/468.html" rel="external">"Antimalarial drugs: An overview"</a>.)</p><p>No ACT has been proven to be superior to any other; the compounds differ slightly in their stability, oral absorption, bioavailability, metabolism, and adverse event profile. Clinical studies evaluating the efficacy of these agents are summarized in the table  (<a class="graphic graphic_table graphicRef107437" href="/d/graphic/107437.html" rel="external">table 3</a>). Local drug resistance patterns should inform treatment guidelines. (See <a class="local">'Artemisinin-resistant malaria'</a> below.)</p><p>The total artemisinin dose (10 to 12 mg/kg) is given over three days. In areas of artemisinin resistance, a six-day course of treatment is warranted [<a href="#rid13">13</a>]. A three-day regimen covers two asexual cycles such that only a small fraction of parasites remain for clearance by the partner drug, thus reducing potential for development of resistance to the partner drug. Administration of a five-day course has not been associated with clinical superiority over a three-day course [<a href="#rid14">14</a>]. (See <a class="local">'Artemisinin-resistant malaria'</a> below.) </p><p>Patients who are not able to tolerate oral medication require initial treatment with rectal or parenteral drug administration until they are able to tolerate oral medication; subsequently, a full three-day course of oral ACT should be administered. The rectal and parenteral regimens are as described separately for treatment of severe malaria. (See  <a class="medical medical_review" href="/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p>Patients with mild malaria and hyperparasitemia (4 to 10 percent) are at increased risk of treatment failure and warrant close monitoring in a hospital setting if feasible [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H270369410"><span class="h4">If ACT is not readily available</span><span class="headingEndMark"> — </span>As noted above, we favor use of artemisinin combination therapy (ACT) for treatment of uncomplicated malaria due to <em>P. falciparum</em> (irrespective of <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> sensitivity) [<a href="#rid3">3</a>]. (See <a class="local">'General approach'</a> above.)</p><p>However, in the case of chloroquine-sensitive <em>P. falciparum</em> where ACT is not readily available, we favor treatment with <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> or <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid1">1</a>]. </p><p>Regions with chloroquine-sensitive malaria include Haiti, the Dominican Republic, most regions of the Middle East, and Central America west of the Panama Canal  (<a class="graphic graphic_figure graphicRef72797 graphicRef103385 graphicRef142995" href="/d/graphic/72797.html" rel="external">figure 2A-C</a>). Additional information summarizing drug resistance by country is available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmalaria%2Ftravelers%2Fcountry_table%2Fp.html&amp;token=ayNIhhJaRWBBmPhCXLAzhg14OC0JACSFrPkb83WaQHpPwp7Haqh9GxPl9KqfbV%2BDFWzEO7KrBJh8zEjpzXVt5g%3D%3D&amp;TOPIC_ID=5704" target="_blank">online</a> [<a href="#rid15">15</a>].</p><p>Dosing for administration of <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> is outlined in the table  (<a class="graphic graphic_table graphicRef72019" href="/d/graphic/72019.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/468.html" rel="external">"Antimalarial drugs: An overview"</a>.)</p><p>In the setting of exposure to a region with unknown prevalence of <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> resistance, or uncertain exposure history, treatment for chloroquine-resistant <em>P. falciparum</em> should be administered. (See <a class="local">'General approach'</a> above.)</p><p class="headingAnchor" id="H909816047"><span class="h3">Recurrent infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent falciparum malaria</strong> - Recurrence of <em>P. falciparum</em> malaria can result from recrudescence (treatment failure) or reinfection; these may be difficult to distinguish. Treatment failure can occur as a result of drug resistance or inadequate drug exposure (due to underdosing, poor adherence, vomiting, pharmacokinetic factors, or substandard medication).</p><p></p><p class="bulletIndent1">In general, treatment failure may be assumed in the setting of lack of resolution of fever and parasitemia or recurrence of these findings within 28 days of treatment; reinfection may be assumed in the setting of fever and parasitemia &gt;28 days following treatment [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">For patients with recurrent infection ≤28 days following treatment for uncomplicated malaria (likely attributable to recrudescence [treatment failure]), we are in agreement with the WHO, which favors treatment with an alternative ACT known to be effective in the region [<a href="#rid2">2</a>]. Retreatment with the same ACT may be reasonable (particularly in settings where there is no second ACT available); one study noted similar retreatment outcomes between patients retreated the same ACT versus an alternative ACT [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">For patients with recurrent infection &gt;28 days following treatment for uncomplicated malaria (likely attributable to reinfection), we are in agreement with the WHO, which favors treatment with a first-line ACT [<a href="#rid2">2</a>]. However, reuse of <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> within 60 days of initial treatment has been associated with an increased risk for neuropsychiatric reactions; therefore, if mefloquine was administered during initial treatment, an alternative regimen should be used.</p><p></p><p class="bulletIndent1">When possible, suspected treatment failure should be confirmed parasitologically, with microscopy or rapid diagnostic tests (RDTs). RDTs based on lactate dehydrogenase are preferred for diagnosis of treatment failure, since RDTs based on histidine-rich protein 2 may remain positive for weeks after treatment of the initial infection, in the absence of recrudescence. (See  <a class="medical medical_review" href="/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria", section on 'Rapid diagnostic tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing risk of vivax infection following falciparum malaria (for areas co-endemic for </strong><strong><em>vivax </em></strong><strong>and</strong><strong><em> falciparum </em></strong><strong>malaria)</strong> – In some areas co-endemic for <em>P. vivax </em>and <em>P. falciparum </em>malaria, the greatest risk of recurrent parasitemia is due to <em>P. vivax</em> malaria rather than <em>P. falciparum</em> [<a href="#rid17">17,18</a>]. It has been hypothesized that acute <em>P. falciparum</em> infection may reactivate <em>P. vivax</em> hypnozoites. In these areas, it has been proposed that administering antirelapse therapy ("radical cure") with <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> to patients with <em>P. falciparum </em>infection may reduce their risk of subsequent <em>P. vivax</em> parasitemia. (See  <a class="medical medical_review" href="/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae", section on 'Preventing relapse'</a>.)</p><p></p><p class="bulletIndent1">In a randomized trial including more than 490 patients with uncomplicated <em>P. falciparum</em> monoinfection and glucose-6-phosphate dehydrogenase (G6PD) activity ≥70 percent in Bangladesh, Indonesia, and Ethiopia, patients were treated with artemisinin combination therapy (ACT; <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> or dihydroartemisinin–piperaquine) and then randomly assigned to receive either radical cure with <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> (total dose 7 mg/kg over 7 days) or standard care in endemic settings with low <em>P. falciparum</em> transmission (consisting of primaquine 0.25 mg/kg single dose) to reduce transmissibility of treated<em> P. falciparum</em> infection [<a href="#rid19">19</a>]. At day 63, the incidence risk of <em>P. vivax </em>parasitemia was lower in the intervention arm (11 versus 2.5 percent; hazard ratio 0.20, 95% CI 0.08–0.51). There were no serious adverse events related to primaquine. </p><p></p><p class="bulletIndent1">The benefits of implementing these findings may vary with geographical location and risk of coinfection [<a href="#rid20">20</a>], the ACT regimen and its associated duration of post treatment prophylaxis [<a href="#rid18">18</a>], and the availability of G6PD screening and treatment adherence.</p><p></p><p class="headingAnchor" id="H4118771064"><span class="h3">Reducing transmissibility</span><span class="headingEndMark"> — </span>Gametocytes may persist in the blood after successful treatment of infection  (<a class="graphic graphic_figure graphicRef79113" href="/d/graphic/79113.html" rel="external">figure 1</a>); they are not harmful to the patient but serve as a source of ongoing transmission. <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">Artemether-lumefantrine</a> has been shown to be superior to non-artemisinin antimalarial drugs in reducing gametocytemia [<a href="#rid21">21</a>]. <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">Primaquine</a> has activity against mature gametocytes but no effect on asexual blood-stage parasites.</p><p>To further reduce transmissibility of treated <em>P. falciparum</em> infection in endemic areas with low transmission, we are in agreement with the WHO which favors administration of <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> (0.25 mg/kg single dose) on the first day of malaria treatment to nonpregnant adults and children ≥6 months [<a href="#rid2">2,3,6,9,22-24</a>].</p><p>This approach is supported by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2022 meta-analysis of <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> efficacy for reducing transmissibility when given in combination with different ACTs for among more than 2500 participants in 14 studies (13 conducted in Africa), primaquine reduced gametocyte carriage (as assessed by polymerase chain reaction [PCR]) on days 7 and 14 (odds ratio [OR] 0.22, 95% CI 0.17-0.28 and OR 0.12, 95% CI 0.08-0.16, respectively); in addition, primaquine was associated with nearly complete prevention of transmission to mosquitoes in three of the studies [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2018 systematic review including 24 randomized trials, addition of <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> (single low dose) added to ACT therapy reduced infectiousness of humans to mosquitoes on day 3 or 4 (from 14 to 2 percent) and was as effective as higher doses of primaquine [<a href="#rid26">26</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">Primaquine</a> should be avoided in pregnant women and infants &lt;6 months of age given the particular vulnerability of these patient groups; the approach to preventing relapse in such cases is discussed separately. (See  <a class="medical medical_review" href="/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment", section on 'Non-falciparum malaria'</a>.)</p><p><a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">Primaquine</a> can cause hemolysis in individuals with G6PD deficiency; however, G6PD testing is not required for patients receiving primaquine for reducing transmission given the relatively low dose for this indication. In one study including 274 Senegalese patients with mild malaria randomized to ACT plus primaquine (0.25 mg/kg, single dose) versus ACT alone, the mean reduction in hemoglobin at day 7 was equivalent [<a href="#rid27">27</a>]. Among 54 patients with G6PD deficiency, the drop in hemoglobin was 0.63 g/dL greater in those who received primaquine than in those who received an ACT alone. (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Inciting drugs, chemicals, foods, illnesses'</a>.)</p><p class="headingAnchor" id="H3318276557"><span class="h2">Outside endemic areas</span></p><p class="headingAnchor" id="H333494751"><span class="h3">General approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment considerations</strong> − Uncomplicated malaria can progress to severe illness in nonimmune individuals within hours to days, so it is important that there is no delay in diagnosis, that treatment be initiated promptly, and that patients be hospitalized if possible.</p><p></p><p class="bulletIndent1">Patients on malaria prophylaxis who develop malaria infection should receive a different antimalarial regimen for treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available regimens</strong> − There are a number of treatment regimens available. We are in agreement with the WHO which recommends ACTs for treatment of uncomplicated <em>P. falciparum</em> malaria [<a href="#rid3">3</a>]; however, guidelines based on local drug availability must be taken into account. Regimens include ACTs, <a class="drug drug_general" data-topicid="8704" href="/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, quinine-based regimens, and <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a>  (<a class="graphic graphic_table graphicRef72019" href="/d/graphic/72019.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef107438" href="/d/graphic/107438.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ACTs</strong> − Issues related to ACTs are discussed above. (See <a class="local">'Selecting an ACT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8704" href="/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> − Atovaquone-proguanil is a well-tolerated and effective treatment for uncomplicated falciparum malaria in patients who were not taking this agent for prophylaxis during the period of exposure to malaria [<a href="#rid28">28</a>]. This is a good alternative to <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> in patients with high body mass index for reasons noted above. The use of atovaquone-proguanil in resource-limited settings is limited by cost. Studies of atovaquone-proguanil conducted in Southeast Asia, South America, and Africa have demonstrated cure rates of &gt;95 percent with no severe adverse side effects [<a href="#rid29">29,30</a>]. Several studies have demonstrated higher efficacy of the atovaquone-proguanil combination over chloroquine-based therapy and <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Quinine-based regimens</strong> − An alternative regimen consists of <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> sulfate administered in combination with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, or <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>. Quinine-based regimens are effective but are less preferable due to bitter taste, cinchonism (reversible tinnitus and reversible high-tone hearing loss), and gastrointestinal side effects [<a href="#rid33">33-35</a>]. Doxycycline and tetracycline are preferred over clindamycin as quinine partner drugs since they are associated with greater efficacy. For infections acquired in Southeast Asia, treatment consists of quinine (seven days) plus doxycycline, tetracycline, or clindamycin (seven days). For infections acquired outside Southeast Asia, treatment consists of quinine (three days) plus doxycycline, tetracycline, or clindamycin (seven days).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mefloquine-based regimens</strong> − Mefloquine-based regimens should be used only when the above regimens are not available; <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> has been associated with neuropsychiatric effects and resistance in some areas [<a href="#rid36">36</a>]. Outside the Thai-Myanmar-Cambodia area, mefloquine cures 90 to 95 percent of <em>P. falciparum</em> malaria. Within the Thai-Myanmar-Cambodia area, mefloquine cure rates have dropped to 60 percent due to resistance [<a href="#rid37">37-39</a>].</p><p></p><p class="headingAnchor" id="H867488039"><span class="h3">Recrudescence</span><span class="headingEndMark"> — </span>For patients with recrudescence (treatment failure) outside endemic areas, treatment should consist of an alternative antimalarial regimen in case of drug resistance to the initial regimen  (<a class="graphic graphic_table graphicRef72019" href="/d/graphic/72019.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef107438" href="/d/graphic/107438.html" rel="external">table 2</a>).</p><p>In addition, evaluation for coinfection with <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> should be pursued, as these species can cause relapse due to their hypnozoite stage. Identification of coinfection with these species requires treatment of the asexual stage as well as <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/d/drug information/118521.html" rel="external">tafenoquine</a> for treatment of hypnozoites. (See  <a class="medical medical_review" href="/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"</a>.)</p><p class="headingAnchor" id="H621891109"><span class="h2">Artemisinin-resistant malaria</span></p><p class="headingAnchor" id="H2605214411"><span class="h3">Scope</span><span class="headingEndMark"> — </span>Artemisinin resistance was initially observed in Southeast Asia and has been observed in sub-Saharan Africa and South America. Key aspects of WHO recommendations to manage artemisinin-resistant malaria include surveillance of molecular markers for drug resistance (including artemisinins and partner drugs), investigation of treatment failures, treatment scale-up, interventions for prevention and elimination, and new drug development [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H1246069745"><span class="h4">Southeast Asia</span><span class="headingEndMark"> — </span>In western Cambodia, where artemisinin monotherapy has been used, prolonged <em>P. falciparum</em> parasite clearance times have been observed, relative to parasites in northwestern Thailand (where artemisinins have been used in combination therapy) [<a href="#rid13">13,41-43</a>]. In a study published in 2009 including 80 patients (40 in western Cambodia and 40 in northwestern Thailand) randomly assigned to treatment with oral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> monotherapy or combination therapy with artesunate and <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a>, the median parasite clearance time was longer among the Cambodian patients (84 versus 48 hours) [<a href="#rid42">42</a>]. </p><p>Subsequently, in 2012, prolonged parasite clearance time in the setting of artemisinin use was described in western Thailand; this is believed to have developed locally rather than by importation of resistant parasites from Cambodia, since no genotypes in Thailand matched those in western Cambodia [<a href="#rid44">44</a>].</p><p>In 2014, <em>P. falciparum</em> artemisinin resistance was noted across Southeast Asia and was observed to occur in association with mutations in the kelch protein gene on chromosome 13 (<em>kelch13</em>) [<a href="#rid13">13,45</a>]. The prevalence of artemisinin K13 propeller mutations varies greatly by region; rates as high as 47 percent in parts of Myanmar have been observed. Spread of artemisinin-resistant parasites is due to transmission of single clones across regions; however, individual populations of parasites can develop artemisinin resistance independently, which may make containment of artemisinin-resistant parasites more challenging [<a href="#rid46">46-48</a>]. One report from China noted delayed parasite clearance following artemisinin treatment of infection due to <em>P. falciparum</em> caused by organisms harboring a single K13 mutation [<a href="#rid49">49</a>].</p><p>In 2016, a prospective study of dihydroartemisinin-piperaquine including 81 Cambodian patients in a region with established artemisinin resistance noted parasite recrudescence in 46 percent of cases. The parasites had the artemisinin resistance–associated <em>kelch13</em> mutations but also had increased the half maximal inhibitory concentration (IC<sub>50</sub>) to piperaquine, suggesting that resistance in the partner drug was also an important component of clinical resistance to ACTs [<a href="#rid23">23</a>]. Treatment of malaria in this region should consist of <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> plus <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a>.</p><p>In 2019, analyses were published on the spread of multidrug-resistant colineage of <em>P. falciparum</em> named KEL1/PLA1 (2008 to 2013), which are strains that contain the <em>kelch13</em> C580Y mutation associated with artemisinin resistance and an amplification of <em>plasmepsin 2/3</em> associated with piperaquine resistance. These parasites were associated with high rates of treatment failure following artemisinin-piperaquine in Southeast Asia (Thailand, Cambodia, Vietnam). Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016 to 2017, its prevalence had risen to higher than 50 percent in all of the surveyed countries except for Laos. In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80 percent of the most recent <em>P. falciparum</em> parasites. Sublineages had also developed mutations in the <em>crt</em> gene, associated with treatment failure. These data underscore that treatment of malaria in this region should consist of <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> plus <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> at present [<a href="#rid50">50,51</a>].</p><p>In areas where other ACTs are failing, use of artesunate-pyronaridine has received a positive scientific opinion from the European Medicines Agency [<a href="#rid52">52</a>]. In a study including 155 adults and children in Vietnam with uncomplicated <em>P. falciparum</em> malaria (including regions with high prevalence of C580Y) treated with pyronaridine-artesunate for 3 days, clinical and parasitologic response at day 42 was demonstrated in more than 96 percent of cases (95% CI 91.4-98.2) [<a href="#rid53">53</a>].</p><p>In 2019, an analysis from eastern India reported a 15 percent rate of treatment failure among patients with uncomplicated malaria treated with artesunate-sulfadoxine-pyrimethamine; treatment failure was associated with a novel G625R polymorphism in <em>kelch13</em> [<a href="#rid54">54</a>]. Factors contributing to the emergence of drug failures in this region include importation of artemisinin-resistant isolates due to migration as well as high frequency of resistance to sulfadoxine-pyrimethamine (resulting in de facto monotherapy with artemisinin).</p><p class="headingAnchor" id="H4164103440"><span class="h4">Sub-Saharan Africa</span><span class="headingEndMark"> — </span>Artemisinin resistance has been reported in Uganda and Rwanda:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uganda</strong> – In a longitudinal study in Northern Uganda between 2017 and 2019 including 240 patients with <em>P. falciparum</em> infection treated with <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a>, prolonged parasite clearance (half-life &gt;5 hours) was observed in 14 patients (5.8 percent of cases) [<a href="#rid55">55</a>]. Of these, 13 patients were infected with <em>P. falciparum</em> parasites with mutations in the A675V or C469Y allele of the <em>kelch13</em> gene. In addition, between 2015 and 2019, the prevalence of parasites with <em>kelch13</em> mutations increased from 3.9 to 19.8 percent.</p><p></p><p class="bulletIndent1">In a surveillance study including more than 6500 blood samples collected from patients in Uganda with uncomplicated malaria between 2016 and 2022, the prevalence of parasites with <em>kelch13</em> validated or candidate resistance markers reached more than 20 percent by 2021 to 2022 in 11 of the 16 districts [<a href="#rid56">56</a>]. Mutations in the A675V or C469Y allele of the <em>kelch13</em> gene reached a combined prevalence of 10 to 54 percent across much of northern Uganda. By 2022, the R561H mutation reached a prevalence of 23 percent in one southwestern district, and the P441L mutation reached a prevalence of 12 to 23 percent in three western districts. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rwanda</strong> – In a 2018 study including 228 Rwandan children age 6 to 59 months wi<em>th P. falciparum</em> infection treated with <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> for three days, 20 participants had detectable parasitemia by microscopy on day 3 after starting treatment (a WHO criterion for partial artemisinin resistance) [<a href="#rid57">57</a>]. Day 3 parasitemia was observed more frequently among patients with isolates containing t<em>he kelch13</em> R561H mutation than among patients with wildtype isolates (39 versus 5 percent). T<em>he kelch13 </em>R561H mutation has arisen independent of the partial artemisinin resistance allele found in Thailand.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eritrea</strong> – In a study including 841 patients with uncomplicated malaria in Eritrea treated with ACT (<a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a>–amodiaquine or artemether–lumefantrine) between 2016 and 2019, the percentage of patients with parasitemia on day 3 increased from 0.4 to 4.2 percent during the study period [<a href="#rid58">58</a>]. ACT resistance was associated with a novel mutation (R622I) in the <em>kelch13</em> gene; the prevalence of this mutation increased from 8.6 to 21.0 percent during the study period. T<em>he hrp2</em> deletion (which impedes parasite production of histidine-rich protein [HRP], the target of widely used malaria rapid diagnostic tests [RDTs]), was observed more frequently among parasites with the R622I mutation than among parasites without it (69 versus 23 percent). The emergenc<em>e of P. falciparum</em> parasites that are both artemisinin-resistant and elude diagnosis by widely used RDTs could compromise malaria control by delaying diagnosis as well as effective treatment of malaria infection.<strong> </strong></p><p></p><p class="bulletIndent1">Issues related to RDTs are discussed further separately. (See  <a class="medical medical_review" href="/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria", section on 'Rapid diagnostic tests'</a>.)</p><p></p><p class="headingAnchor" id="H3560496465"><span class="h4">South America</span><span class="headingEndMark"> — </span>Independent emergence of<em> a kelch13 </em>mutant allele has been described in Guyana [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H4066975876"><span class="h3">Detection</span><span class="headingEndMark"> — </span>Artemisinin resistance should be considered in individuals with relevant epidemiologic exposure (residence in or travel to regions where resistance has been reported). Artemisinin resistance alone typically does not cause treatment failure, unless there is also resistance in the ACT partner drug [<a href="#rid60">60</a>].</p><p>The evaluation of a malaria blood smear on day 3 of treatment with an ACT is a useful screening tool for presence of artemisinin resistance. Artemisinin resistance is unlikely if the proportion of patients with parasite density &gt;100,000 parasites/microL is less than 3 percent following a three-day course of ACT therapy [<a href="#rid61">61</a>]. </p><p>If there is a concern for artemisinin resistance, consultation with an infectious disease physician or contacting the CDC Malaria Hotline should be considered. The CDC Malaria Hotline (770-488-7788) is available Monday to Friday, 9 a.m. to 5 p.m., Eastern time. Outside these hours, providers should call 770-488-7100 and ask to speak with a CDC malaria expert. </p><p class="headingAnchor" id="H3094958204"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The optimal approach to treatment of artemisinin-resistant malaria is uncertain. For patients with infection acquired in Southeast Asia and initial parasite density of &gt;100,000 parasites/microL who have &gt;3 percent parasitemia on day three of ACT treatment, we extend the duration of treatment to six days and follow daily smears until negative; the patient should be managed with expert consultation if feasible. This approach is supported by an open-label study including more than 1200 adults and children with uncomplicated P. falciparum in 10 countries (7 in Asia and 3 in Africa) treated with oral <a class="drug drug_general" data-topicid="17088" href="/d/drug information/17088.html" rel="external">artesunate</a> for three days followed by a standard 3-day course of ACT [<a href="#rid13">13</a>]. In western Cambodia (where treatment success with ACTs is declining), the 6-day course of antimalarial therapy was associated with a cure rate of 98 percent (95% CI 91-99) at 42 days. </p><p>Use of a triple ACT (TACT) regimen has been proposed as an alternative approach to treatment of artemisinin-resistant malaria. In a randomized trial including 1100 patients with uncomplicated <em>P. falciparum</em> malaria from eight countries (Cambodia, Thailand, Laos, Vietnam, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo), the efficacy of three standard ACTs (dihydroartemisinin-piperaquine, artesunate-mefloquine, and <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a>) was compared with two TACT regimens containing partner drugs with opposing resistance mechanisms (dihydroartemisinin-piperaquine plus <a class="drug drug_general" data-topicid="9602" href="/d/drug information/9602.html" rel="external">mefloquine</a> or artemether-lumefantrine plus amodiaquine) [<a href="#rid62">62</a>]. In regions with ACT resistance (Cambodia, Thailand, and Vietnam), efficacy (defined by 42-day PCR-corrected clinical and parasitologic response) was more favorable among patients who received TACT (dihydroartemisinin-piperaquine plus mefloquine) than standard ACT (dihydroartemisinin-piperaquine; 98 versus 48 percent; risk difference 0.51, 95% CI 0.42-0.59). This result was driven by the high rate of piperaquine resistance in the region; the 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine was noninferior to that of artesunate-mefloquine at three sites in Cambodia (96 versus 95 percent; risk difference 1 percent, 95% CI -6 to 8). </p><p>An alternative strategy to TACT in this region consists of avoiding piperaquine combination therapy. At study sites with no established artemisinin resistance, all regimens had excellent efficacy; the tolerability and toxicity of the TACTs were similar to those of the ACTs. The study was limited by a lack of blinding and by a relative lack of pediatric participants, who are the highest risk group for malaria worldwide but who make up a small proportion of malaria cases in areas with ACT resistance. Use of TACTs in regions with artemisinin resistance requires follow-up study of safety and tolerability.</p><p class="headingAnchor" id="H701208827"><span class="h2">Patients with HIV infection</span><span class="headingEndMark"> — </span>In general, the approach to treatment of malaria is the same in human immunodeficiency virus (HIV)-infected and HIV-uninfected patients.</p><p>Potential drug interactions between antimalarials and antiretroviral drugs should be reviewed carefully. In patients with HIV and uncomplicated malaria, artesunate-sulfadoxine-pyrimethamine should be avoided if the patient is on <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and artesunate-amodiaquine should be avoided if the patient is on <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> or <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a> [<a href="#rid2">2,3,6</a>].</p><p class="headingAnchor" id="H3788067485"><span class="h1">FOLLOW-UP MONITORING</span><span class="headingEndMark"> — </span>Follow-up blood smears are appropriate to document declining parasite density [<a href="#rid63">63-66</a>]. In general, parasitemia typically clears within 48 to 72 hours with appropriate therapy [<a href="#rid64">64,67,68</a>].</p><p>We are in agreement with the United States Centers for Disease Control and Prevention (CDC) which advises repeat blood smears every 12 to 24 hours to monitor parasitologic response to treatment [<a href="#rid66">66</a>]. In resource-limited settings, many clinicians perform follow-up smears only for patients who do not improve clinically (with defervescence within 72 hours). (See  <a class="medical medical_review" href="/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria", section on 'Quantification of parasitemia'</a>.)</p><p>In individuals who do not clinically improve and have persistent parasitemia, considerations include inadequate drug dosing, poor absorption, inadequate adherence, and/or drug resistance. Issues related to dosing and adherence should be reviewed carefully. Consideration of treatment with an alternative regimen is warranted, particularly if drug resistance is a possibility. In the United States, CDC clinicians are available through the malaria hotline: 770-488-7788 or 855-856-4713; during off-hours, call 770-488-7100 and ask to have the malaria clinician on call paged. </p><p>Malaria can recrudesce; repeat evaluation for malaria should be pursued in the event of a subsequent febrile episode. (See <a class="local">'Recurrent infection'</a> above.)</p><p class="headingAnchor" id="H2686383343"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113035.html" rel="external">"Society guideline links: Malaria"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Uncomplicated falciparum malaria consists of symptomatic <em>Plasmodium falciparum</em> infection with a positive parasitologic test and parasitemia &lt;4 percent, in the absence of symptoms consistent with severe malaria  (<a class="graphic graphic_table graphicRef107439" href="/d/graphic/107439.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimalarial selection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General approach</strong> – For treatment of uncomplicated <em>P. falciparum</em> malaria, we suggest treatment with artemisinin combination therapy (ACT) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For individuals &gt;65 kg treated with an ACT, we suggest use of an agent other than <a class="drug drug_general" data-topicid="9066" href="/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef107438" href="/d/graphic/107438.html" rel="external">table 2</a>). (See <a class="local">'General approach'</a> above and <a class="local">'Selecting an ACT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients on malaria prophylaxis</strong> – Patients on malaria prophylaxis who develop malaria infection should receive a different medication for treatment. (See <a class="local">'Antimalarial selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chloroquine-sensitive malaria</strong> – For patients with chloroquine-sensitive <em>P. falciparum</em> in settings where ACT is not readily available, we suggest treatment with <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> or <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef72019" href="/d/graphic/72019.html" rel="external">table 4</a>). (See <a class="local">'General approach'</a> above and <a class="local">'If ACT is not readily available'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reducing transmissibility</strong> – To reduce transmissibility of treated <em>P. falciparum</em> infection in endemic areas with low transmission, we suggest administration of <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> (0.25 mg/kg single dose) on the first day of malaria treatment to nonpregnant adults and children ≥6 months (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Primaquine should be avoided in pregnant women and infants &lt;6 months of age. (See <a class="local">'Reducing transmissibility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Artemisinin-resistant malaria</strong> – Artemisinin resistance should be considered in individuals with relevant epidemiologic exposure (residence in or travel to regions where resistance has been reported). Artemisinin resistance alone typically does not cause treatment failure unless there is also resistance in the ACT partner drug. For patients who may have artemisinin-resistant malaria, daily smears should be followed until negative. For patients with initial parasite density &gt;100,000 parasites/microL and &gt;3 percent parasitemia on day three of ACT treatment, we suggest extending the duration of treatment to six days (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Artemisinin-resistant malaria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up monitoring</strong> – Follow-up blood smears are appropriate to document declining parasite density. In general, parasitemia typically clears within 48 to 72 hours with appropriate therapy. (See <a class="local">'Follow-up monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent infection</strong> – Recurrent <em>P. falciparum</em> malaria infection can result from recrudescence (treatment failure) or reinfection; these may be difficult to distinguish. (See <a class="local">'Recurrent infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In general, treatment failure may be assumed in the setting of lack of resolution of fever and parasitemia (or recurrence of these findings) within 28 days of treatment for uncomplicated malaria; for such patients, we suggest therapy with an alternative ACT known to be effective in the region (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In general, reinfection may be assumed in the setting of fever and parasitemia &gt;28 days following treatment for uncomplicated malaria; for such patients, we suggest treatment with a first-line ACT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recrudescence</strong> – For patients with recrudescence outside endemic areas, treatment should consist of an alternative antimalarial regimen, in case of drug resistance to the initial regimen. In addition, evaluation for coinfection with <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> should be pursued, as these species can cause relapse due to their hypnozoite stage. Identification of coinfection with these species requires treatment of the asexual stage as well as <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/d/drug information/118521.html" rel="external">tafenoquine</a> for treatment of hypnozoites. (See <a class="local">'Outside endemic areas'</a> above and  <a class="medical medical_review" href="/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"</a> and  <a class="medical medical_review" href="/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevention. Treatment Guidelines: Treatment of Malaria (Guidelines for Clinicians), 2013. http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf (Accessed on May 11, 2020).</li><li class="breakAll">Guidelines for the Treatment of Malaria, World Health Organization, Geneva 2015.</li><li class="breakAll">World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</li><li><a class="nounderline abstract_t">Mace KE, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2018. MMWR Surveill Summ 2022; 71:1.</a></li><li class="breakAll">World Health Organization. WHO model list of essential medicines. https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1 (Accessed on March 09, 2019).</li><li class="breakAll">World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on November 30, 2022).</li><li><a class="nounderline abstract_t">Newton P, White N. Malaria: new developments in treatment and prevention. Annu Rev Med 1999; 50:179.</a></li><li><a class="nounderline abstract_t">Douglas NM, Nosten F, Ashley EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 2011; 52:612.</a></li><li><a class="nounderline abstract_t">Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673.</a></li><li><a class="nounderline abstract_t">Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Int Health 2008; 13:1111.</a></li><li><a class="nounderline abstract_t">Sondén K, Wyss K, Jovel I, et al. High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series. Clin Infect Dis 2017; 64:199.</a></li><li><a class="nounderline abstract_t">Hatz C, Soto J, Nothdurft HD, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 2008; 78:241.</a></li><li><a class="nounderline abstract_t">Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371:411.</a></li><li><a class="nounderline abstract_t">Whalen ME, Kajubi R, Goodwin J, et al. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clin Infect Dis 2023; 76:443.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Malaria Information and Prophylaxis, by Country [A]. http://www.cdc.gov/malaria/travelers/country_table/a.html (Accessed on March 21, 2016).</li><li><a class="nounderline abstract_t">Mavoko HM, Nabasumba C, da Luz RI, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Glob Health 2017; 5:e60.</a></li><li><a class="nounderline abstract_t">Commons RJ, Simpson JA, Thriemer K, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19:91.</a></li><li><a class="nounderline abstract_t">Hossain MS, Commons RJ, Douglas NM, et al. The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Med 2020; 17:e1003393.</a></li><li><a class="nounderline abstract_t">Thriemer K, Degaga TS, Christian M, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Lancet 2023; 402:2101.</a></li><li><a class="nounderline abstract_t">Ashley EA, Phyo AP, Carrara VI, et al. Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity. J Infect Dis 2019; 220:100.</a></li><li><a class="nounderline abstract_t">Ippolito MM, Johnson J, Mullin C, et al. The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis. Clin Infect Dis 2017; 65:486.</a></li><li><a class="nounderline abstract_t">White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012; 11:418.</a></li><li><a class="nounderline abstract_t">Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357.</a></li><li><a class="nounderline abstract_t">Lin JT, Ubalee R, Lon C, et al. Microscopic Plasmodium falciparum Gametocytemia and Infectivity to Mosquitoes in Cambodia. J Infect Dis 2016; 213:1491.</a></li><li><a class="nounderline abstract_t">Stepniewska K, Humphreys GS, Gonçalves BP, et al. Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis. J Infect Dis 2022; 225:1215.</a></li><li><a class="nounderline abstract_t">Graves PM, Choi L, Gelband H, Garner P. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 2018; 2:CD008152.</a></li><li><a class="nounderline abstract_t">Tine RC, Sylla K, Faye BT, et al. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. Clin Infect Dis 2017; 65:535.</a></li><li><a class="nounderline abstract_t">Blanshard A, Hine P. Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2021; 1:CD004529.</a></li><li><a class="nounderline abstract_t">Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60:533.</a></li><li><a class="nounderline abstract_t">de Alencar FE, Cerutti C Jr, Durlacher RR, et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997; 175:1544.</a></li><li><a class="nounderline abstract_t">Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999; 179:1587.</a></li><li><a class="nounderline abstract_t">Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999; 60:526.</a></li><li><a class="nounderline abstract_t">Pasvol G, Newton CR, Winstanley PA, et al. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg 1991; 45:702.</a></li><li><a class="nounderline abstract_t">Stanley J. Malaria. Emerg Med Clin North Am 1997; 15:113.</a></li><li><a class="nounderline abstract_t">Looareesuwan S, Wilairatana P, Vanijanonta S, et al. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet 1992; 339:369.</a></li><li><a class="nounderline abstract_t">Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996; 42:415.</a></li><li><a class="nounderline abstract_t">Looareesuwan S, Viravan C, Vanijanonta S, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 1992; 339:821.</a></li><li><a class="nounderline abstract_t">Luxemburger C, ter Kuile FO, Nosten F, et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88:213.</a></li><li><a class="nounderline abstract_t">Maguire JD, Krisin, Marwoto H, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067.</a></li><li class="breakAll">World Health Organization. Malaria: Q&amp;A on artemisinin resistance. https://www.who.int/malaria/media/artemisinin_resistance_qa/en/ (Accessed on November 09, 2020).</li><li><a class="nounderline abstract_t">Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366:1298.</a></li><li><a class="nounderline abstract_t">Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455.</a></li><li><a class="nounderline abstract_t">Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851.</a></li><li><a class="nounderline abstract_t">Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960.</a></li><li><a class="nounderline abstract_t">Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 2015; 15:683.</a></li><li><a class="nounderline abstract_t">Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015; 211:670.</a></li><li><a class="nounderline abstract_t">Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015; 15:415.</a></li><li><a class="nounderline abstract_t">Nyunt MH, Hlaing T, Oo HW, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis 2015; 60:1208.</a></li><li><a class="nounderline abstract_t">Huang F, Takala-Harrison S, Jacob CG, et al. A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. J Infect Dis 2015; 212:1629.</a></li><li><a class="nounderline abstract_t">van der Pluijm RW, Imwong M, Chau NH, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis 2019; 19:952.</a></li><li><a class="nounderline abstract_t">Hamilton WL, Amato R, van der Pluijm RW, et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect Dis 2019; 19:943.</a></li><li class="breakAll">https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-new-anti-malaria-treatment-use-outside-european-union_en.pdf (Accessed on November 20, 2020).</li><li><a class="nounderline abstract_t">Quang Bui P, Hong Huynh Q, Thanh Tran D, et al. Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018). Clin Infect Dis 2020; 70:2187.</a></li><li><a class="nounderline abstract_t">Das S, Manna S, Saha B, et al. Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India. Clin Infect Dis 2019; 69:1144.</a></li><li><a class="nounderline abstract_t">Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med 2021; 385:1163.</a></li><li><a class="nounderline abstract_t">Conrad MD, Asua V, Garg S, et al. Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. N Engl J Med 2023; 389:722.</a></li><li><a class="nounderline abstract_t">Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis 2021; 21:1120.</a></li><li><a class="nounderline abstract_t">Mihreteab S, Platon L, Berhane A, et al. Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea. N Engl J Med 2023; 389:1191.</a></li><li><a class="nounderline abstract_t">Chenet SM, Akinyi Okoth S, Huber CS, et al. Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana. J Infect Dis 2016; 213:1472.</a></li><li class="breakAll">World Health Organization. Malaria. Q&amp;A on artemisinin resistance. https://www.who.int/malaria/media/artemisinin_resistance_qa/en/ (Accessed on June 11, 2020).</li><li><a class="nounderline abstract_t">Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010; 201:570.</a></li><li><a class="nounderline abstract_t">van der Pluijm RW, Tripura R, Hoglund RM, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet 2020; 395:1345.</a></li><li><a class="nounderline abstract_t">White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.</a></li><li><a class="nounderline abstract_t">Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Treatment of Malaria: Guidelines For Clinicians (United States). Part 2: General Approach to Treatment and Treatment of Uncomplicated Malaria. http://www.cdc.gov/malaria/diagnosis_treatment/clinicians2.html (Accessed on November 09, 2012).</li><li class="breakAll">Centers for Disease Control and Prevention. Treatment of Malaria: Guidelines for Clinicians (United States). https://www.cdc.gov/malaria/resources/pdf/treatment_guidelines_101819.pdf (Accessed on February 11, 2020).</li><li><a class="nounderline abstract_t">Bouchaud O, Mühlberger N, Parola P, et al. Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J 2012; 11:212.</a></li><li><a class="nounderline abstract_t">Das D, Price RN, Bethell D, et al. Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J 2013; 12:125.</a></li></ol></div><div id="topicVersionRevision">Topic 5704 Version 69.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevention. Treatment Guidelines: Treatment of Malaria (Guidelines for Clinicians), 2013. http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf (Accessed on May 11, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for the Treatment of Malaria, World Health Organization, Geneva 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/guidelines-for-malaria" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36048717" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Malaria Surveillance - United States, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36048717" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Malaria Surveillance - United States, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36048717" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Malaria Surveillance - United States, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073271" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Malaria: new developments in treatment and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292666" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20832366" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657092" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986683" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256423" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075834" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Spread of artemisinin resistance in Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36130191" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36130191" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840069" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30587297" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33211712" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37979594" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30698794" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28402391" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23237606" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26774243" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26667316" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Microscopic Plasmodium falciparum Gametocytemia and Infectivity to Mosquitoes in Cambodia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778875" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29393511" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605472" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33459345" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348225" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180204" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Atovaquone and proguanil for the treatment of malaria in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228090" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348224" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1763797" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9056573" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346445" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8904612" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347854" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036679" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575721" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575721" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22475593" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19641202" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Artemisinin resistance in Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22940027" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484134" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877962" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180241" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25704894" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537878" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25910630" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345710" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345709" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345709" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31251812" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30535043" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551228" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Evidence of Artemisinin-Resistant Malaria in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37611122" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864801" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37754284" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26690347" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26690347" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20085495" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : In vivo parasitological measures of artemisinin susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171078" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703186" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The treatment of malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519416" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of malaria in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519416" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of malaria in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519416" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of malaria in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22720832" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602021" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Early parasitological response following artemisinin-containing regimens: a critical review of the literature.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
